3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Cardiotoxicity
7
Neoplasms
3
Heart Failure
3
Breast Neoplasms
3
Cardiovascular Diseases
2
Ventricular Dysfunction, Left
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Metabolic Syndrome
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Long QT Syndrome
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Dyslipidemias
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Cardiomyopathies
1
Brugada Syndrome
1
Bone Marrow Diseases
1
Atrial Fibrillation
1
Arrhythmias, Cardiac
1
Interventions
pembrolizumab
1
ibrutinib
1
Watchful Waiting
1
Sertraline
1
Quality of Life
1
Electrocardiography
1
Clinical Laboratory Techniques
1
Bone Marrow Transplantation
1
Bone Marrow Examination
1
Biopsy
1
Azacitidine
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Bone Marrow Diseases
×
Electrocardiography
×
Clear all
NCT07387354
2026-03-16
MDS
Thomas Jefferson University
Phase 1/2
Not yet recruiting
25 enrolled